IP Library Granted Patent US 8,703,777
Granted Patent B2
US 8,703,777 · App. 12/811,695 · Granted Apr 22, 2014

Certain chemical entities, compositions and methods

Inventors: Pingda Ren (San Diego, CA); Yi Liu (San Diego, CA); Troy Edward Wilson (San Marino, CA); Katrina Chan (San Diego, CA); Christian Rommel (La Jolla, CA); Liansheng Li (San Diego, CA)
Assignee: Intellikine LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,777
App. No.
12/811,695
Granted
Apr 22, 2014
Kind
B2
Abstract

Provided herein are substituted bicyclic compounds, e.g., compounds of Formula IV, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for inhibiting phosphatidyl inositol-3 kinase (PI3 kinase), e.g., for the treatment of various diseases and conditions associated with PI3 kinase activity, including but not limited to, cancer, inflammatory disease, immune disease, and respiratory disease.

Claims (62)

1. A compound of Formula IV:

or a pharmaceutically acceptable salt thereof, wherein

W a 2 is CR 5 ;

W a 3 is CR 6 ;

W a 4 is CR 7 ;

W d is

R a is hydrogen, halo, phosphate, urea, carbonate, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, or heterocycloalkyl;

R 11 is hydrogen, alkyl, halo, amino, amido, hydroxy, or alkoxy;

R 12 is hydrogen, alkyl, cyano, alkynyl, alkenyl, halo, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, amino, carboxylic acid, alkoxycarbonyl, or amido;

B is alkyl, amino, heteroalkyl, cycloalkyl, heterocycloalkyl, or a moiety of Formula II:

W c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl;

q is an integer of 0, 1, 2, 3, or 4;

X is a bond or —(CH(R 9 )) z —;

Y is a bond, —O—, —S—, —S(═O)—, —S(═O) 2 —, —N(R 9 )—, —C(═O)—(CHR 9 ) z —, —C(═O)—, —N(R 9 )—C(═O)NH—, or —N(R 9 )C(R 9 ) 2 —;

each z is independently 1, 2, 3, or 4;

R 1 is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, or carbonate;

R 2 is alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, or nitro;

R 3 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, aryl, or heteroaryl;

R 5 , R 6 , R 7 , and R 8 are independently hydrogen, C 1 -C 4 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 3 -C 5 cycloalkyl, C 1 -C 4 heteroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 amido, amino, acyl, C 1 -C 4 acyloxy, C 1 -C 4 sulfonamido, halo, cyano, hydroxy, or nitro; and

each R 9 is independently hydrogen, C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, or C 2 -C 10 heteroalkyl.

2. The compound of claim 1 , wherein the compound is of Formula V or Formula VI:

3. The compound of claim 1 , wherein the compound is of Formula VII:

4. The compound of claim 1 , wherein R 1 is selected from hydrogen, alkyl, and halo.

5. The compound of claim 4 , wherein R 1 is hydrogen, methyl, isopropyl, or fluoro.

6. The compound of claim 1 , wherein R 3 is —H, halo, alkyl, alkoxy, or cycloalkyl.

7. The compound of claim 6 , wherein R 3 is —H, —CH 3 , —CH 2 CH 3 , —CF 3 , —Cl, or —F.

8. The compound of claim 7 , wherein R 3 is methyl or chloro.

9. The compound of claim 1 , wherein R 5 is H, —CN, —NH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CF 3 , NO 2 , or halo.

10. The compound of claim 1 , wherein R 6 is H, —CN, —NH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CF 3 , NO 2 , or halo.

11. The compound of claim 1 , wherein R 7 is H, —CN, —NH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CF 3 , NO 2 , or halo.

12. The compound of claim 1 , wherein R 8 is H, —CN, —NH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CF 3 , NO 2 , or halo.

13. The compound of claim 1 , wherein X is —CH 2 — or —CH(CH 3 )—.

14. The compound of claim 13 , wherein —CH(CH 3 )— is in an (S) stereochemical configuration.

15. The compound of claim 1 , wherein X is —CH 2 — and Y is a bond.

16. The compound of claim 1 , wherein W c is aryl or heterocycloalkyl.

17. The compound of claim 1 , wherein W d is 4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl,

6-amino-9H-purin-9-yl, or

7-amino-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl.

18. The compound of claim 1 , wherein W d is

19. The compound of claim 18 , wherein W d is

wherein R 11 is H, alkyl, halo, amino, amido, hydroxy, or alkoxy, and

R 12 is H, alkyl, alkynyl, alkenyl, halo, aryl, heteroaryl, heterocycloalkyl, or cycloalkyl.

20. The compound of claim 19 , wherein the compound is of Formula 6-A:

21. The compound of claim 20 , wherein B is alkyl, amino, aryl, heteroalkyl, heteroaryl, heterocycloalkyl, or cycloalkyl.

22. The compound of claim 20 , wherein B is aryl, alkyl, cycloalkyl, heteroaryl, or heterocycloalkyl.

23. The compound of claim 22 , wherein B is optionally substituted phenyl, methyl, ethyl, isopropyl, cyclopropyl, cyclopentyl, optionally substituted pyridinyl, or tetrahydropyranyl.

24. The compound of claim 20 , wherein B is a moiety of Formula II:

wherein W c is phenyl;

R 1 is H, —F, —Cl, —CN, —CH 3 , isopropyl, —CF 3 , —OCH 3 , nitro, or phosphate;

R 2 is hydroxy or cyano; and

q is an integer of 0 or 1.

25. The compound of claim 20 , wherein R 12 is —I, —Br,

26. The compound of claim 25 , wherein R 12 is

27. A pharmaceutical composition comprising a compound of claim 1 , 19 , or 20 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

28. The compound of claim 1 , wherein the compound is of Formula 2-A:

29. The compound of claim 1 , wherein the compound is of Formula 2-B:

30. The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

31. The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

32. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

33. The compound of claim 18 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

34. The compound of claim 28 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

35. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:

Assignments (2)
CHANGE OF NAME Recorded Aug 2, 2012
From: INTELLIKINE, INC.
To: INTELLIKINE LLC
Reel/Frame 028712/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2011
From: REN, PINGDA; LIU, YI; WILSON, TROY EDWARD; LI, LIANSHENG; CHAN, KATRINA; ROMMEL, CHRISTIAN
To: INTELLIKINE, INC.
Reel/Frame 025680/0179 →
Continuity (5)
Continuation In Part PCTUS2009000038 · Jan 5, 2009
Provisional Application 61009971 · Jan 4, 2008
Provisional Application 61194294 · Sep 26, 2008
Provisional Application 61201146 · Dec 5, 2008
Related Publication 20110046165A1 · Feb 24, 2011